Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lasalocid is a polyether carboxylic ionophore antibiotic produced by the bacterium *Streptomyces lasaliensis*. It functions as a mobile carrier, selectively binding and transporting monovalent (e.g., Na+, K+) and divalent (e.g., Ca2+) cations across biological membranes. This disruption of transmembrane ion gradients leads to osmotic lysis of target parasites, making it an effective anticoccidial agent. It also exhibits antibacterial activity, primarily against gram-positive microorganisms. Lasalocid is predominantly used in veterinary medicine as a medicated feed additive to prevent coccidiosis and promote growth in livestock, including poultry and cattle.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lasalocid.